The Efficacy of H89 on Aquaporin 5 Levels in Asthmatic Rat Models

Basit Öğe Kaydı
dc.contributor.authorSaygin, M.
dc.contributor.authorOzturk, O.
dc.contributor.authorAsci, H.
dc.contributor.authorBayram, D.
dc.contributor.authorCandan, I. A.
dc.date.accessioned2026-01-24T12:26:50Z
dc.date.available2026-01-24T12:26:50Z
dc.date.issued2024
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground: The effect of a specific protein kinase A inhibitor H89 on Aquaporin 5 (AQ5) levels, which has a role in the inflammation of asthma pathogenesis, was investigated in this study. Objective: To prove that H89, which was thought to be a promising agent, may show anti-inflammatory activity in the treatment of asthma by causing inhibition of the protein kinase A enzyme that is involved in inflammation. Methods: Thirty-two Wistar-Albino adult male rats, ranging between 250 and 350 g, were divided into four groups: (a) control group; (b) sham group, administration of 1 ml ovalbumin (OVA) solution intraperitonal (IP) and 0.1 ml OVA dissolved in dimethyl sulfoxide intranasally; (c) asthma group, IP + intranasally OVA administration; and (d) H89 group, (IP + intranasally OVA) + 0.1 ml H89. The lungs of the rats were evaluated histopathologically and immunohistochemically at the end of the study. Results: The histopathological changes and AQ5 levels of the sham and asthma groups were not statistically different (p > 0.05). However, the parameters were found to be increased in the asthma group compared with the control group (p < 0.001). The alveolar degeneration and vascular congestion were statistically significantly decreased in the H89 group (p < 0.05). The AQ5 levels were reduced in the H89 group, but the difference was not statistically significant. Conclusion: Aquaporin 5 levels and histopathological changes were increased in asthmatic patients, and an improvement was detected with H89 treatment. H89 has an effect on the inflammation of asthma pathogenesis, so it can be thought to be used in asthma treatment. However, more studies are needed to find out the therapy duration and ideal doses of H89 treatment.
dc.identifier.doi10.7727/wimj.2016.313
dc.identifier.endpage41
dc.identifier.issn0043-3144
dc.identifier.issn2309-5830
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85189460428
dc.identifier.scopusqualityQ4
dc.identifier.startpage37
dc.identifier.urihttps://doi.org/10.7727/wimj.2016.313
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4958
dc.identifier.volume71
dc.identifier.wosWOS:001277972500009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherUniv West Indies Faculty Medical Sciences
dc.relation.ispartofWest Indian Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectAsthma
dc.subjectAquaporin 5
dc.subjectH89
dc.subjectovalbumin
dc.subjectprotein kinase A
dc.titleThe Efficacy of H89 on Aquaporin 5 Levels in Asthmatic Rat Models
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
wimj-iss1-2024_37_41.pdf
Boyut:
2.88 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu